Recent Treatment for Management of Inflammatory Bowl Disease

Due to the development of biologics and small molecule medicines (SMDs), there has been a substantial shift in the approach that is taken to treat inflammatory bowel disease (IBD). This shift has been brought about by the introduction of these treatments. It is important to note that these treatments will not be effective to each and every patient, and it is quite likely that a "ceiling effect" will take place when biologic monotherapy is delivered. Taking into consideration this predicament, it is evident that there is a requirement that has not yet been fulfilled for the purpose of maximising the utilisation of biologics and being able to anticipate therapeutic responses. For the purpose of treating patients who are experiencing either an initial lack of response or a subsequent loss of response to traditional biologics and SMDs, there is an urgent requirement for the development of novel medications that have innovative action mechanisms. It has been suggested that a unique method might be utilised in order to improve the efficacy of treatment for inflammatory bowel disease (IBD). This is due to the fact that the combination of several biologics or SMDs has the capability to reduce inflammation in a variety of different ways. According to the evidence that is currently available for inflammatory bowel disease (IBD), individuals who have refractory IBD and who have not responded to several biologic treatments or who have extraintestinal symptoms may benefit from dual targeted therapy. Equally as crucial is the identification of the proportion of patients suffering from inflammatory bowel disease (IBD) who are responding favourably to biological combination therapy in order to maintain remission of the condition. The objective of this review is to present a synopsis of the newly developed biologics and SMDs, as well as the current state of bio-logics and SMDs. This is done with the intention of highlighting the progress that has been achieved towards the development of personalised treatment for inflammatory bowel disease (IBD).